Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118383 | 0.90 | CYP3A4 (0.44) | LMNACYP1A2CYP3A4MAOATSHR | |
| SCHEMBL30232965 | 0.88 | CYP3A4 (0.41) | LMNACYP1A2CYP3A4MAOATSHR | |
| SCHEMBL23588775 | 0.88 | CYP3A4 (0.41) | LMNACYP1A2CYP3A4MAOATSHR | |
| SCHEMBL20118660 | 0.87 | LMNA (0.49) | LMNACYP1A2CYP3A4MAOATSHR | |
| SCHEMBL20118526 | 0.87 | LMNA (0.57) | LMNACYP1A2CYP3A4MAOATSHR | |
| SCHEMBL7975413 | 0.83 | SMN1; SMN2 (0.40) | LMNATSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL7061424 | 0.82 | NPC1 (0.63) | LMNACYP1A2CYP3A4TSHRCYP2C9 | |
| SCHEMBL7057167 | 0.82 | NPC1 (0.63) | LMNACYP1A2CYP3A4TSHRCYP2C9 | |
| SCHEMBL20118355 | 0.81 | PHLPP2 (0.62) | LMNACYP1A2CYP3A4MAOATSHR | |
| SCHEMBL7062605 | 0.78 | PLAU (0.43) | LMNACYP1A2CYP3A4MAOATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2018081513-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | KLKB1, SERPINB1, KLK1 | LMNA 1628/4885CYP1A2 516/4885CYP3A4 773/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | LMNA 1628/4885CYP1A2 516/4885CYP3A4 773/4885 |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | LMNA 1628/4885CYP1A2 516/4885CYP3A4 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.